Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.52 |
| ▸ | RAB9A | P51151 | 7/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | TP53 | P04637 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449960 | 0.84 | GRM5 (0.39) | NPC1RAB9ASMN1; SMN2PKMGRM5 | |
| SCHEMBL6461180 | 0.82 | GRM5 (0.40) | NPC1RAB9ASMN1; SMN2GRM5MAPT | |
| SCHEMBL6454528 | 0.81 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2PKMGRM5 | |
| SCHEMBL6457450 | 0.81 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL6452145 | 0.78 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2HSP90AA1CYP19A1 | |
| SCHEMBL6457310 | 0.77 | MAPT (0.41) | NPC1SMN1; SMN2MAPTTP53MEN1 | |
| SCHEMBL6448498 | 0.77 | SMN1; SMN2 (0.53) | NPC1RAB9ASMN1; SMN2PKML3MBTL1 | |
| SCHEMBL7158427 | 0.75 | CASP3 (0.49) | NPC1RAB9ASMN1; SMN2PKMGRM5 | |
| SCHEMBL7188135 | 0.74 | CASP3 (0.42) | NPC1RAB9ASMN1; SMN2PKMGRM5 | |
| SCHEMBL6451515 | 0.73 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2HSP90AA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | NPC1 59/4885RAB9A 2483/4885SMN1; SMN2 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.